One Drop announced today that new peer-reviewed research demonstrates sustained blood glucose reductions with its diabetes platform. New York-based One Drop presented the clinical health outcomes associated with the long-term use of its digital diabetes offering at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. The results demonstrated clinically sustained and […]
Drug-Device Combinations
Walmart unveils telehealth offering for managing diabetes
Walmart announced today that its MeMD national telehealth provider partner launched the Walmart Health Virtual Care Diabetes Program. The platform, available as a standalone or as part of a comprehensive medical and behavioral telehealth program, was developed for employers and payors to help their employees and members close gaps in diabetes management among employees and […]
Analysis backs use of Abbott’s FreeStyle Libre CGM in type 1, type 2 diabetes
Abbott (NYSE:ABT) announced today that a new real-world meta-analysis provided positive data for its FreeStyle Libre system. The analysis of 75 real-world observational studies of the FreeStyle Libre continuous glucose monitoring (CGM) system demonstrated significant reductions in glycated hemoglobin (HbA1c) sustained for up to 24 months in adults with both type 1 and type 2 […]
Study results show improved time in range with Diabeloop automated insulin delivery system
Diabeloop announced today that study data support the use of its DBLG1 hybrid closed-loop automated insulin delivery system. Paris-based Diabeloop’s real-life German cohort data, presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona, show a constant improvement in time in range (70-180 mg/dL) combined with a significant reduction of hypoglycemia. According […]
Study supports use of PharmaJet’s needle-free vaccine delivery systems
PharmaJet announced today that study data demonstrated increased immunogenicity when using its needle-free delivery system. Golden, Colorado-based PharmaJet presented the research results for the needle-free vaccine injection technology last week at the World Vaccine Congress. PharmaJet’s needle-free systems have been incorporated into clinical studies for multiple RNA and DNA vaccine and therapeutic development programs thanks […]
Study shows sustained improvements with Medtronic’s MiniMed 780G with Guardian 4
Medtronic (NYSE:MDT) announced today that the extended study phase of its MiniMed 780G insulin pump system produced positive data. Fridley, Minnesota-based Medtronic presented new data from the study of MiniMed 780G with the no-calibration, non-adjunctive Guardian 4 sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona. Data demonstrated sustained improvements in […]
Abbott, Camdiab, Ypsomed forge partnership for automated insulin delivery
Abbott (NYSE:ABT) announced today that it partnered with CamDiab and Ypsomed (SWX:YPSN) to produce an integrated automated insulin delivery (AID) system. The companies announced the partnership at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, Spain. It seeks to develop and commercialize the integrated AID system with an initial focus centered around […]
Insulet announces positive study data for Omnipod 5 for type 1, type 2 diabetes
Insulet (Nasdaq:PODD) today unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes. Acton, Massachusetts-based Insulet presented results from studies as well as user experience data for both type 1 and type 2 diabetes at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, […]
Impel NeuroPharma rebrands to Impel Pharmaceuticals as part of corporate transformation
Impel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand. Seattle-based Impel develops proprietary Precision Olfactory Delivery (POD) technology to treat patients suffering from diseases across a range of areas in addition to the central nervous system. The company’s Trudhesa nasal spray for treating migraine in […]
EMA gives positive opinion on Novo Nordisk’s human insulin with flexible storage
Novo Nordisk (NYSE:NVO) announced that the European Medicines Agency (EMA) granted a positive opinion on a storage update for insulin. EMA’s positive opinion relates to a proposed update to the storage conditions of two human insulins: Actrapid (short-acting insulin) and Insulatard (intermediate-acting insulin). Bagsværd, Denmark-based Novo Nordisk said in a news release that the EMA’s […]